Navigation Links
A new role for milk: Delivering polyphenols with anti-cancer activity
Date:12/19/2013

Philadelphia, PA, December 19, 2013 Polyphenols found in tea manifest anti-cancer effects but their use is limited by poor bioavailability and disagreeable taste. A new study in the Journal of Dairy Science finds that when epigallocatechin gallate (EGCG), the major extractable polyphenol in green tea and the most biologically active, when diluted in skim milk or other milk complexes remains bioactive and continues to reduce colon cancer cell proliferation in culture at concentrations higher than 0.03 mg of EGCG/mL.

"These results support a new role for milk as an ideal platform for delivery of bioactive compounds and opens the door to a new generation of dairy products providing additional benefits to human health," say authors Sanaz Haratifar and Milena Corredig, of the Department of Food Science and Department of Human Health and Nutritional Sciences of the University of Guelph, Ontario, Canada.

The majority of extractable polyphenols in tea are flavan-3-ols, commonly referred to as catechins. EGCG is the major catechin found in tea. Tea polyphenols have been shown to inhibit tumor formation, reduce cancer cell proliferation, increase normal cell death (apoptosis), and/or suppress the formation of new blood vessels feeding tumors (angiogenesis). For several reasons, tea catechins have poor bioavailability and the goal of the current study was to encapsulate EGCG in casein (milk protein) molecular aggregates, known as micelles, to maintain and enhance catechin bioavailability.

In one experiment, human colorectal cancer cells (HT-29) were grown for 24 hours in the presence of EGCG in water or dispersed in milk. The number of living cancer cells (cell viability) was measured, and it was shown that EGCG reduced cell viability in a dose-dependent fashion although at higher concentrations (0.15 mg/mL and above), the antiproliferative effect of EGCG in water was greater than in milk.

Another experiment evaluated cancer cell proliferation after EGCG was added to different milk products, including skim milk, milk whey, and milk serum. While some differences were noted in cell proliferation at lower concentrations between EGCG in control medium and EGCG diluted in the milk components, at higher EGCG concentrations (0.8 mg/mL and above), EGCG reduced cancer cell growth by 80% or more, whether diluted in milk or not.

"In order to exert their biological health benefits in vivo, polyphenols must be available and still active, even when present in a food matrix," comments Dr. Haratifar. "This study showed that the binding of EGCG to the casein micelles did not affect the bioefficacy of EGCG and cell uptake at concentrations higher than 0.03 mg of EGCG/mL of skim milk."


'/>"/>

Contact: Eileen Leahy
jdsmedia@elsevier.com
732-238-3628
Elsevier Health Sciences
Source:Eurekalert

Related biology news :

1. Nanotherapy: Treating deadly brain tumors by delivering big radiation with tiny tools
2. Small packages delivering huge results
3. Researchers engineer a hybrid 5 times more effective in delivering genetic material into cells
4. Sticking power of plant polyphenols used in new coatings
5. University of Hawaii Cancer Center researchers create new anti-cancer drug
6. Molecular movies may accelerate anti-cancer drug discovery
7. Biologists engineer algae to make complex anti-cancer designer drug
8. New study highlights strong anti-cancer properties of soybeans
9. New Research: Modified Citrus Pectin - A Potent Anti-Cancer Therapy
10. USC scientists ID protein that regulates cellular trafficking, potential for anti-cancer therapy
11. Trial combining anti-cancer drug and radiotherapy may lead to treatment for brain tumor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
Breaking Biology News(10 mins):
(Date:6/14/2017)... ... June 14, 2017 , ... ... of its Phase 1 clinical study of AC0058, a novel irreversible Bruton’s ... B cell-related autoimmune diseases, including rheumatoid arthritis and systemic lupus erythematosus. ...
(Date:6/14/2017)... ... June 14, 2017 , ... Delpor, Inc. ( Delpor ... Phase II SBIR grant from the National Institute of Diabetes and Digestive and Kidney ... ). , The product is based on Delpor’s NANOPOR™ technology ...
(Date:6/13/2017)... ... June 13, 2017 , ... ... advanced flexible materials, has chosen The Copley Consulting Group to facilitate and ... Technologies is aligning its manufacturing operations and strategic initiatives to increasing customer ...
(Date:6/13/2017)... ... June 13, 2017 , ... Exxact Corporation, a leading ... that it will offer the new NVIDIA® DGX Station™ and DGX-1™ systems featuring ... , “NVIDIA’s DGX portfolio is paving the way for a new era of ...
Breaking Biology Technology: